Daratumumab biosimilar (Biocad)

达雷妥尤单抗生物类似药 (Biocad)

Report date: 2024/03/14 20:00:41

Base Information

Drug NameDaratumumab biosimilar (Biocad)
Drug Alias NameBCD-264
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cellular phagocytosis (ADCP) effectsAnti-CD38Complement dependent cytotoxicity (CDC) effects +[4] 
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A